In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covidien boosts endoscopy offering with New Wave, while recall hits sales

This article was originally published in Clinica

Executive Summary

Covidien has reportedly paid $100m to acquire New Wave Surgical, a developer of laparoendoscopic surgical devices. The deal was announced on New Wave’s website on 28 March but was only widely reported last week, with the $100m fee unconfirmed but cited by several news outlets. Pompano Beach, Florida-based New Wave has developed a device called D-Help that keeps laparoscopic lenses clean and “defogged” during surgery. The product received US FDA 510(k) clearance in 2006, and was used in its millionth procedure in February. D-Help will be sold by Covidien as the Clearify visualization system – but apart from that, New Wave says existing customers will see little impact. But Covidien’s marketing reach should boost uptake of the device.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT101499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel